Aurinia Pharmaceuticals Inc.

Based in Edmonton, Alberta, Aurinia Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases with limited treatment options. The company's primary commercial product is LUPKYNIS (voclosporin), an oral immunosuppressant approved for treating active lupus nephritis in adult patients. This represents the company's main revenue stream in the United States and Japan, where it targets patients with this serious kidney manifestation of systemic lupus erythematosus.

Beyond its marketed therapy, Aurinia maintains a clinical-stage pipeline centered on aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand being evaluated for potential use across multiple autoimmune indications. The company operates with approximately 128 full-time employees and maintains operations focused on North American and Japanese markets, reflecting its geographic concentration in developed healthcare systems where specialty pharmaceutical pricing and patient access support commercial viability.